Changeflow GovPing Healthcare & Life Sciences High-Bioactivity Goat Colostrum Powder Preparat...
Routine Guidance Added Final

High-Bioactivity Goat Colostrum Powder Preparation Method

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has published a patent application detailing a method for preparing a high-bioactivity goat colostrum composite freeze-dried powder. The invention focuses on enhancing the stability and survival rate of probiotics within the powder through encapsulation techniques.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a patent application (US20260083675A1) filed with the USPTO, describing a novel preparation method for a high-bioactivity goat colostrum composite freeze-dried powder. The method involves specific ratios of goat colostrum powder, composite probiotic liposome freeze-dried powder, and mannose oligosaccharides. Key to the invention is the preparation of modified phytosterol and chitosan to encapsulate probiotics, thereby protecting them and improving their survival rate.

This patent application does not impose immediate regulatory obligations on companies. However, it signifies potential innovation in the food and pharmaceutical sectors related to probiotic stability and delivery. Companies involved in developing or manufacturing probiotic supplements or functional foods may find this technology relevant for future product development or licensing opportunities. Compliance officers should note this as a development in the intellectual property landscape for such products.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

HIGH-BIOACTIVITY GOAT COLOSTRUM COMPOSITE FREEZE-DRIED POWDER AND PREPARATION METHOD THEREOF

Application US20260083675A1 Kind: A1 Mar 26, 2026

Inventors

Boxing Chen, Lei Zhang

Abstract

A high-bioactivity goat colostrum composite freeze-dried powder relates to the technical field of food, comprising the following components in parts by weight: 60-70 parts of goat colostrum powder, 5-8 parts of composite probiotic liposome freeze-dried powder, and 6-9 parts of mannose oligosaccharides; the composite probiotic liposome freeze-dried powder is prepared from the following components: gallic acid, phytosterol, soybean phosphatidylcholine, modified chitosan, and probiotic powder; the probiotic powder is Bifidobacterium longum powder or Lactobacillus acidophilus powder. The invention proposes to prepare modified phytosterol by esterification reaction of gallic acid and phytosterol, and to prepare probiotic liposomes by encapsulating probiotics with the modified phytosterol and soybean phosphatidylcholine, and at the same time introduce carboxymethyl into chitosan to prepare modified chitosan, and to prepare composite probiotic liposome freeze-dried powder by encapsulating probiotic liposomes with the modified chitosan, thereby protecting probiotics, thereby reducing the inactivation of probiotics, and improving their survival rate.

CPC Classifications

A61K 9/1277 A61K 9/19 A61K 35/20 A61K 35/745 A61K 35/747 A61K 47/26

Filing Date

2024-10-22

Application No.

18923357

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
October 22nd, 2024
Instrument
Guidance
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083675A1

Who this affects

Applies to
Drug manufacturers Food manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 3114 Food & Beverage Manufacturing 3254.1 Biotechnology
Activity scope
Drug Labeling Product Development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Product Development
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Food Safety Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!